BR9910149A - éster inibidor de spla2 - Google Patents

éster inibidor de spla2

Info

Publication number
BR9910149A
BR9910149A BR9910149-1A BR9910149A BR9910149A BR 9910149 A BR9910149 A BR 9910149A BR 9910149 A BR9910149 A BR 9910149A BR 9910149 A BR9910149 A BR 9910149A
Authority
BR
Brazil
Prior art keywords
ester
spla
spla2
inhibitory
inhibitor
Prior art date
Application number
BR9910149-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Michael Lyle Denney
John Michael Morin Jr
Daniel Jon Sall
Jason Scott Sawyer
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR9910149A publication Critical patent/BR9910149A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR9910149-1A 1998-05-01 1999-04-20 éster inibidor de spla2 BR9910149A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8387398P 1998-05-01 1998-05-01
PCT/US1999/008538 WO1999056752A1 (en) 1998-05-01 1999-04-20 sPLA2 INHIBITOR ESTER

Publications (1)

Publication Number Publication Date
BR9910149A true BR9910149A (pt) 2001-10-02

Family

ID=22181214

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9910149-1A BR9910149A (pt) 1998-05-01 1999-04-20 éster inibidor de spla2

Country Status (22)

Country Link
EP (1) EP1073440B1 (https=)
JP (1) JP4459441B2 (https=)
KR (1) KR20010071197A (https=)
CN (1) CN1303290A (https=)
AT (1) ATE280155T1 (https=)
AU (1) AU755901B2 (https=)
BR (1) BR9910149A (https=)
CA (1) CA2331036A1 (https=)
DE (1) DE69921314T2 (https=)
EA (1) EA003277B1 (https=)
ES (1) ES2230847T3 (https=)
HR (1) HRP20000738A2 (https=)
HU (1) HUP0201636A1 (https=)
ID (1) ID27812A (https=)
IL (1) IL139203A0 (https=)
NO (1) NO315940B1 (https=)
NZ (1) NZ507391A (https=)
PL (1) PL344571A1 (https=)
SK (1) SK16332000A3 (https=)
TR (1) TR200003198T2 (https=)
WO (1) WO1999056752A1 (https=)
ZA (1) ZA200005561B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140327A (en) * 1999-05-12 2000-10-31 Eli Lilly And Company Morpholino-n-ethyl ester derivative of an indole sPLA2 inhibitor
AU2252201A (en) * 1999-12-16 2001-06-25 Eli Lilly And Company Carbon monoxide-based synthesis of spla2 inhibitors
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
CN1450893A (zh) * 2000-07-14 2003-10-22 伊莱利利公司 治疗脓毒症的方法
EA200971020A1 (ru) * 2007-05-03 2010-10-29 Антера Фармасьютикалз, Инк. Лечение сердечно-сосудистого заболевания и дислипидемии с использованием ингибиторов секреторной фосфолипазы а(spla) и способы комбинированного лечения с ингибитором spla
US8048880B2 (en) 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
US20150335498A1 (en) * 2014-05-22 2015-11-26 The Procter & Gamble Company Heterogenous mass containing foam
US10729600B2 (en) 2015-06-30 2020-08-04 The Procter & Gamble Company Absorbent structure
BR112018009100A8 (pt) 2015-11-04 2019-02-26 Procter & Gamble estrutura absorvente
WO2017079601A1 (en) 2015-11-04 2017-05-11 The Procter & Gamble Company Absorbent structure
WO2017079599A1 (en) 2015-11-04 2017-05-11 The Procter & Gamble Company Absorbent structure

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2036307C (en) * 1990-03-08 2002-07-09 Susan Jean Ward 3-arylcarbonyl-1-aminoalkyl-1h-indole-containing antiglaucoma compositions and method
PL180523B1 (pl) * 1994-04-01 2001-02-28 Eli Lilly & Co Nowy zwiazek, pochodna 1H-indolo-3-glioksylamidu i srodek farmaceutyczny PL PL PL PL PL PL PL PL PL PL
DE4435477A1 (de) * 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indol- und -azaindol-derivate
FI974437A7 (fi) * 1995-06-06 1997-12-05 Pfizer Substituoituja N-(indoli-2-karbonyyli)amideja ja johdannaisia glykogee nifosforylaasi-inhibiittoreina
AU1940800A (en) * 1998-12-21 2000-07-12 Eli Lilly And Company Combination therapy for the treatment of sepsis

Also Published As

Publication number Publication date
IL139203A0 (en) 2001-11-25
ES2230847T3 (es) 2005-05-01
ATE280155T1 (de) 2004-11-15
TR200003198T2 (tr) 2001-03-21
AU755901B2 (en) 2003-01-02
NO20005477D0 (no) 2000-10-31
EA003277B1 (ru) 2003-04-24
JP4459441B2 (ja) 2010-04-28
EP1073440B1 (en) 2004-10-20
ZA200005561B (en) 2002-01-10
EP1073440A1 (en) 2001-02-07
CN1303290A (zh) 2001-07-11
HUP0201636A1 (en) 2002-09-28
NZ507391A (en) 2003-12-19
CA2331036A1 (en) 1999-11-11
PL344571A1 (en) 2001-11-05
NO20005477L (no) 2000-10-31
SK16332000A3 (sk) 2001-06-11
EP1073440A4 (en) 2002-07-17
EA200001141A1 (ru) 2001-04-23
AU3652599A (en) 1999-11-23
WO1999056752A1 (en) 1999-11-11
HRP20000738A2 (en) 2001-10-31
DE69921314D1 (de) 2004-11-25
JP2002513761A (ja) 2002-05-14
KR20010071197A (ko) 2001-07-28
DE69921314T2 (de) 2006-02-09
NO315940B1 (no) 2003-11-17
ID27812A (id) 2001-04-26

Similar Documents

Publication Publication Date Title
BR9910149A (pt) éster inibidor de spla2
DK1950200T3 (da) [[3-(2-AMINO-1,2-DIOXOETHYL)-2-ETHYL-1-(PHENYLMETHYL)-11H-INDOL-4-YL]OXY]EDDIKESYREMETHYLESTER SOM sPLA2-INHIBITOR
BRPI0414817A (pt) derivados de ácido indol substituìdos e seu uso como inibidores de pai-l
MXPA05010174A (es) Derivados de indol e indolina sustituidos.
AU2003302626A1 (en) 1, 2, 5-thiadiazolidin-3-one 1, 1 dioxide derivatives as inhibitors of protein tyrosine phosphatase ptp1b
MY127495A (en) Dipeptide derivatives
AU6998000A (en) Substituted indolinones as tyrosine kinase inhibitors
DK1392714T3 (da) Steroider som agonister for FXR
AU2001288374A1 (en) Substituted oxindole derivatives as tyrosine kinase inhibitors
AU3770000A (en) Indolinone compounds as kinase inhibitors
TR200403436T2 (tr) Kristalin 1-metilkarbapenem türevleri.
AU2003239508A1 (en) Indole compounds useful as impdh inhibitors
HUP0102812A3 (en) Pharmaceutical compositions containing the phospholipase inhibitor sodium {[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1h-indol-4-yl]oxy}acetate and process for pruducing them
AU5331499A (en) Indole spla2 inhibitors
AP2001002149A0 (en) Indole derivatives(Priority title)
AU3703499A (en) Substituted indolinones as kinase inhibitors
BR9305991A (pt) Derivados de indol como inibidores da esteróide 5 alfa redutase
EA200501557A1 (ru) Новый способ синтеза (2s)-индолин-2-карбоновой кислоты и использование в синтезе периндоприла
EP0987250A4 (en) INDOLDICARBONIC ACID DERIVATIVES
NO983444L (no) Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5<alfa>-reduktaseinhibitorer
MY136938A (en) New process for the synthesis of perindopril and its pharmaceutically acceptable salts
BR0010448A (pt) éster de morfolino-n-etila derivado de um inibidor de spla2 de indol
EA200300468A1 (ru) Подавление зависимости опухолевых клеток от фактора роста
MY136288A (en) New process for the synthesis of perindopril and its pharmaceutically acceptable salts
EA200600454A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007.